hrp0094p2-317 | Growth and syndromes (to include Turner syndrome) | ESPE2021
Deyanova Y.
, Iotova V.
, Tsochev K.
, Stoyanova M.
, Stoicheva R.
, Mladenov V.
, Bazdarska Y.
, Galcheva S.
, Zenker M.
,
Introduction: Noonan syndrome (NS) is caused by mutations in RAS/MAPK signaling pathway genes. About 70% of the NS patients have short stature, and human recombinant growth hormone (rhGH) is an established yet not fully standardized treatment.Objective: To assess the first 2 years rhGH treatment effectiveness in NS patients at a single centre.Materials and methods: A total of 20 (16 male) NS patien...